ORGANISATION

Attendance Fee

750 € Regular

500 € Member of AGAH, EUFEMED

or Junior Scientist up to the age of 30

The participation fee is per person. Please note, according to §4 para 22 German turnover tax law, registration and workshop fees are exempt from VAT. Registration fees are charged and collected on behalf of AGAH e. V. All bookings are subject to change.

Registration Deadline: September 25, 2023

WORKSHOP VENUE

SocraTec R&D GmbH Im Setzling 35 61440 Oberursel (Germany)

REGISTRATION

CSi Hamburg GmbH

Goernestraße 30

20249 Hamburg (Germany)

Phone: +49 40 30770 300

e-Mail: agah-meetings@csihamburg.de

CONTACT

Arbeitsgemeinschaft für angewandte Humanpharmakologie (AGAH) e.V.

Office: Goernestraße 30 20249 Hamburg (Germany) Phone: +49 40 30772097

e-Mail: info@agah.eu

Web: www.agah.eu · www.studynurse.de

Registration Link https://forms.office.com/e/SmwcsiHdv9

CONTENT

Pharmacokinetics – prerequisite and at the same time "door opener" for understanding pharmacology!

This workshop, developed by experienced specialists from industry, CRO and consultancy, offers an entrée to physiological background, measures, and characteristics of pharmacokinetics. It helps to understand study design and evaluation of PK studies and the conclusions drawn from the results.

The workshop has been developed for clinical investigators, project leaders, project managers and monitors as well as PhD students in industry, hospitals, university and CROs. The knowledge obtained in this applied introductory course helps beginners in pharmacokinetics obtaining the basic knowledge and scientific background for professional handling, evaluation, and interpretation of PK data.

FACULTY

Dr. Stephan Glund

Head of Clinical Pharmacology CREA Boehringer Ingelheim Pharma GmbH & Co. KG Biberach (Germany)

Dr. Roland Heinig

Clinical Pharmacology Bayer AG, Pharmaceuticals Wuppertal (Germany)

Dr. Joachim Höchel

Clinical Pharmacology Bayer AG, Pharmaceuticals Berlin (Germany)

Dr. Frank Runge

Clinical Pharmacology Lead Boehringer Ingelheim Pharma GmbH & Co. KG Biberach (Germany)

Helmut Schütz

BEBAC – Consultancy Services for Bioequivalence and Bioavailability Studies Vienna (Austria)

Dr. Ralph-Steven Wedemeyer

Advisor Biopharmaceutics;
Head of Pharmaceutical Technology
SocraTec R&D GmbH
Oberursel (Germany)



Arbeitsgemeinschaft für angewandte Humanpharmakologie e.V.

Association for Applied Human Pharmacology



OCTOBER 5-6, 2023
OBERURSEL (GERMANY)

PROGRAMME · DAY 1 · October 5. 2023

· nou	TAININE DATE October 3, 2023
08:00	Registration
08:30	Welcome and introduction of participants and speakers
	Joachim Höchel, Berlin; Barbara Schug, Oberursel
08:40	Introduction into basic terms and principles of Pharmacokinetics (PK)
	Joachim Höchel, Berlin
09:00	Human physiology: what you should know
	to better understand pharmacokinetics
	An overview of physiological characteristics being of
	(PK)-relevance for A bsorption, D istribution, M etabolism
	and Elimination (ADME) Roland Heinig, Wuppertal
	Noiuna Heiling, Wappertui
09:45	In vitro ADME & preclinical PK
	Description of in vitro ADME parameters, such as
	Cytochrome P450 & drug transporter inhibition,
	drug absorption, plasma protein binding, and metabolic
	clearance; explanation of preclinical animal PK results
	and their translation to the human situation
	Frank Runge, Biberach
10:45	Break
11:00	Discussion and Questions
11.00	Discussion and Questions
11:15	How to measure what happens in pharmacokinet-
	ics:
	PK metrics of relevance!
	An introduction into how one can quantify what the body
	does to the drug, i.e. which measures describe what hap-
	pens to the drug including relevant methods of calculation
	Helmut Schütz, Vienna
12:00	Break
(
1	W 100

PROGRAMME · DAY 1 · October 5, 2023

13:00 Human PK studies I: bioequivalence, food interaction and drug-drug-interaction studies

Presentation of basic principles and design features such as choice of dosing, treatment and sampling schedule, evaluation approaches as well as population characteristics

Joachim Höchel, Berlin

14:15 Break

14:30 Human PK studies II: Special populations characteristics considering liver, kidney and age

Assessment of factors that relevantly impact PK in patients in adequately designed clinical trial considering authorities requirements Roland Heiniq, Wuppertal

16:00 Break

16:15 Hands-on clinical PK – the practical exercise:

How to design your PK program? An exercise with the goal to plan your own clinical PK program based on a preclinical data set *All*

17:30 Discussion and Questions

18:00 End of Day 1 Workshop Program

18:15 Option of individual consultation of the speakers

Participants are invited to consult individual speakers if they have specific questions/case studies they wish to discuss with an expert.

PROGRAMME · Day 2 · October 6, 2023

08:30 Introduction to biologics: what you should know to understand their pharmacokinetics

An overview of their molecular characteristics which interfere with pharmacokinetics – which types, characteristics and differences are of relevance

Stephan Glund, Biberach

09:00 Human PK – What's different in biologics?

An introduction into bioanalytical methods, antibody development and their assessment, specificities in ADME, TMDD, immunogenicity, drug-drug interaction and comparability

Stephan Glund, Biberach

10:15 Break

10:30 Human PK studies III: interplay between biopharmaceutics and absorption

What you should know about galenics and biopharmaceutics to understand the interplay between formulation principles and pharmacokinetics

Ralph-Steven Wedemeyer, Oberursel

11:30 Discussion and Questions

12:00 Break

13:00 Human PK studies IV: Human drug metabolism

How to determine the overall pathways of metabolism and excretion of an investigational drug and how to use these results in the context of drug safety (MIST, DDI). *Frank Runge, Biberach*

13:45 **Pitfalls in BA/BE**

Attempts in beating Murphy's law: Learnings from failures in study design, bioanalytics and statistics

Helmut Schütz, Vienna

14:30 Break

14:45 Where all ends meet

- PK information in the label

Review of a PK program

– What, When, How – and Why?
All

16:00 End of Workshop